Among second-line treatments for primary biliary cholangitis (PBC), Iqirvo (elafibranor) may work better than Livdelzi (seladelpar) at reducing markers of liver damage, while Livdelzi…
News
CHOLESTASIS
NewsNew ABCB4 mutation found to be cause of PFIC3 in young woman
A new mutation in the ABCB4 gene was found to cause progressive familial intrahepatic cholestasis (PFIC) type 3 in a young woman, a case…
FATTY LIVER DISEASE
NewsLiverMultiScan may lessen need for biopsy in assessing MASLD
Perspectum‘s MRI-based LiverMultiScan improves the diagnostic rate of metabolic dysfunction-associated steatotic liver disease (MASLD) — a form of fatty liver disease —…
BILIARY ATRESIA
NewsCytokine levels may predict Kasai procedure outcome in biliary atresia
Blood levels of certain immune signaling molecules called cytokines may help to predict the likelihood of a successful outcome with the…
The first patient has been enrolled in ECLIPSE 1, a Phase 3 clinical trial testing Vir Biotechnology’s experimental combination of tobevibart and elebsiran in adults…
CHOLANGITIS
NewsTrial testing golexanolone as PBC treatment delayed
A Phase 1b/2 trial testing Umecrine Cognition’s golexanolone in primary biliary cholangitis (PBC) patients with cognitive symptoms and fatigue has been delayed due to…
CHOLESTASIS
NewsABCB4 mutation ID’d as cause of woman’s recurrent cholestasis
A young woman in the U.S. who experienced recurrent cholestasis was later found, with the help of genetic testing, to have a mutation in…
FATTY LIVER DISEASE
NewsIcosabutate fails MASH Phase 2 trial but shows some benefits in liver
Northsea Therapeutics’ oral therapy candidate icosabutate was not superior to a placebo at resolving metabolic dysfunction-associated steatohepatitis (MASH) — a severe form of…
ALAGILLE SYNDROME
NewsMore collaborative Alagille research is needed, review study says
More collaborative research is needed to better understand Alagille syndrome and to help overcome challenges related to diagnosing and treating it, according to a…
Atea Pharmaceuticals plans to launch two parallel Phase 3 trials soon to test its investigational combination therapy of bemnifosbuvir and ruzasvir for people with…
Recent Posts
- For girl in Asia, limited access to genetic testing delayed an Alagille diagnosis
- FDA gives bepirovirsen priority review for chronic hepatitis B
- Starting disease marker levels may shape Iqirvo response in PBC
- The possibility for liver function to improve brings me hope
- New mouse model could help guide PFIC3 treatment research